X

Drug Profile

Actinonin

Alternative Names: VRC 483

Latest Information Update: 30 Sep 2005

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Nonindustrial source; Vicuron Pharmaceuticals
Class
Mechanism of Action Angiogenesis inhibitors; Metalloprotease inhibitors; Peptide hydrolase inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No

Highest Development Phases

No development reported Bacterial infections; Cancer

Most Recent Events

30 Sep 2005 Vicuron Pharmaceuticals has since been acquired by and merged into Pfizer
03 Dec 1999 Preclinical development for Bacterial infections in USA (Unknown route)
13 Mar 1998 A preclinical study has been added to the adverse events and pharmacodynamics sections

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com